Clinical Trial ResultsNuvectis recently presented positive interim data from NXP900’s Phase 1 trial at the 2025 American Association for Cancer Research Meeting, indicating a potentially safe profile and meaningful Src inhibition.
Financial PositionNuvectis ended with $18.5M in cash and no debt, and closed an equity offering receiving net proceeds of $14.4M, providing sufficient capital to fund operations into 2027.
Market PotentialLung cancer represents a significantly large market, and NXP900’s clinical and commercial potential to treat non-small cell lung cancer is viewed positively.